U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07303712) titled 'Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90' on March 17.
Brief Summary: The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
Study Start Date: Aug. 01, 2024
Study Type: OBSERVATIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Recruitment Status: RECRUITING
Sponsor: Palo Alto Veterans Institute for Research
Published by HT Digital Content S...